Tandem Diabetes Care AI Stock Analysis
Tandem Diabetes Care (0M0F) AI Stock Analysis
Tandem Diabetes Care
(LSE:0M0F)
No summary available
Tandem Diabetes Care (0M0F) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $1.40B
- Dividend Yield
- ―
- Average Volume (3M)
- 727
- Price to Earnings (P/E)
- -27.9
- Beta (1Y)
- 1.28
- Revenue Growth
- 6.73%
- EPS Growth
- 76.54%
- Country
- UK
- Employees
- 2,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Tandem Diabetes Care Business Overview & Revenue Model
Company Description
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system,...
Tandem Diabetes Care Earnings Call Summary
The call was broadly positive, supported by record third-quarter revenue and pump shipments, improving U.S. customer starts, international growth, gross-margin expansion, positive adjusted EBITDA for the fifth consecutive quarter, reaffirmed 2026 guidance and progress across the Mobi Tubeless and fully closed-loop pipelines. The main cautions were slower-than-expected pharmacy adoption, related revenue headwinds extending into 2027, infusion-set supply constraints, direct-market transition costs and the unresolved C-peptide requirement for type 2 access.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, worldwide sales are expected to be in the range of $1.065 billion to $1.085 billion, including U.S. sales in the range of $730 million to $745 million and international sales in the range of $335 million to $340 million; gross margins are expected in the range of 56% to 57% and adjusted EBITDA margin of 5% to 6% of annual sales. In the fourth quarter, Tandem anticipates shipping approximately 15% to 20% of pumps and 8% to 10% of installed base supplies through pharmacy, representing nearly 15% of U.S. sales; for the year, PayGo pumps will be more like 10% to 12% and pharmacy as a percent of sales will probably average something more in the low teens, like also 10% to 12%. For 2027, a mid- to high-single digit increase year-over-year is a fair starting point, Mobi Tubeless is expected to reach full commercial availability in the first half of 2027, and direct operations are expected to expand to approximately half of the installed base by the end of next year.
Tandem Diabetes Care Risk Analysis
Tandem Diabetes Care disclosed 63 risk factors in its most recent earnings report. Tandem Diabetes Care reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksTandem Diabetes Care Peers Comparison
Overall Rating
MDT81Outperform
DXCM73Outperform
PODD73Outperform
ABT67Neutral
BBNX60Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $131.58B | 25.15 | 10.60% | 2.78% | 9.77% | 12.28% | |
| 73Outperform | $31.08B | 32.17 | 36.50% | ― | 13.03% | 40.88% | |
| 73Outperform | $10.58B | 24.79 | 29.48% | ― | 26.46% | 75.56% | |
| 67Neutral | $187.95B | 40.19 | 9.11% | 2.32% | 10.00% | -66.06% | |
| 60Neutral | $892.71M | -8.78 | -27.33% | ― | 43.69% | -3.00% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0M0F | Tandem Diabetes Care | 20.02 | 0.89 | 4.66% | |
| ABT | Abbott Laboratories | 108.52 | -18.36 | -14.47% | |
| DXCM | Dexcom | 83.33 | 24.84 | 42.47% | |
| PODD | Insulet | 152.48 | -175.54 | -53.52% | |
| MDT | Medtronic | 102.86 | 9.67 | 10.38% | |
| BBNX | Beta Bionics, Inc. | 16.42 | -10.74 | -39.54% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
